Inicio
Resultado de la búsqueda
3 búsqueda de la palabra clave 'Autoimmune hepatitis'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigaciónCOVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature / Juan Carlos Restrepo Gutiérrez
Título : COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : Journal of Translational Autoimmunity Idioma : Inglés (eng) Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5995 COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022.
Obra : Journal of Translational Autoimmunity
Idioma : Inglés (eng)
Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5995 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001779 AC-2022-001 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-001Adobe Acrobat PDF
Título : Differential characteristics in drug-induced autoimmune hepatitis Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2018 Títulos uniformes : JGH Open Idioma : Inglés (eng) Palabras clave : Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis Resumen : Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P Mención de responsabilidad : Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez Referencia : JGH Open. 2018 May 24;2(3):97-104. DOI (Digital Object Identifier) : 10.1002/jgh3.12054 PMID : 30483571 Derechos de uso : CC BY-NC En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 Differential characteristics in drug-induced autoimmune hepatitis [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, . - 2018.
Obra : JGH Open
Idioma : Inglés (eng)
Palabras clave : Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis Resumen : Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P Mención de responsabilidad : Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez Referencia : JGH Open. 2018 May 24;2(3):97-104. DOI (Digital Object Identifier) : 10.1002/jgh3.12054 PMID : 30483571 Derechos de uso : CC BY-NC En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000756 AC-2018-043 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2018-043.pdfAdobe Acrobat PDF
Título : Serious liver disease induced by infliximab Tipo de documento : documento electrónico Autores : Alejandra María Restrepo Hamid, Fecha de publicación : 2007 Títulos uniformes : Clinical Rheumatology Idioma : Inglés (eng) Palabras clave : Adverse reactions autoimmune hepatitis cholestatic liver disease infliximab rheumatoid arthritis Resumen : Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. Mención de responsabilidad : Gabriel J. Tobon, Carlos Cañas, Juan-Jose Jaller, Juan-Carlos Restrepo & Juan-Manuel Anaya Referencia : Clin Rheumatol. 2007 Apr;26(4):578-81. DOI (Digital Object Identifier) : 10.1007/s10067-005-0169-y PMID : 16547695 En línea : https://link.springer.com/article/10.1007%2Fs10067-005-0169-y Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3450 Serious liver disease induced by infliximab [documento electrónico] / Alejandra María Restrepo Hamid, . - 2007.
Obra : Clinical Rheumatology
Idioma : Inglés (eng)
Palabras clave : Adverse reactions autoimmune hepatitis cholestatic liver disease infliximab rheumatoid arthritis Resumen : Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting. Mención de responsabilidad : Gabriel J. Tobon, Carlos Cañas, Juan-Jose Jaller, Juan-Carlos Restrepo & Juan-Manuel Anaya Referencia : Clin Rheumatol. 2007 Apr;26(4):578-81. DOI (Digital Object Identifier) : 10.1007/s10067-005-0169-y PMID : 16547695 En línea : https://link.springer.com/article/10.1007%2Fs10067-005-0169-y Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3450 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000018 AC-2007-005 Archivo digital Producción Científica Artículos científicos Disponible
